{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-070604","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.639371+00:00","generated_at":"2026-06-25T02:17:58.261510+00:00","sec_items":["5.02","5.07","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Iovance appoints Wendy Dixon to board; retains chairman Dukes after failed re-election","bullets":["Appointed Wendy Dixon, Ph.D. to board effective June 10, 2022; granted RSU valued at $425,000 (8.30/sh).","Chairman Iain Dukes received more withheld votes than for votes at annual meeting; board rejected his conditional resignation.","Dukes' non-independence due to prior consulting agreement expires Dec 2022; board cited valuable contributions.","Stockholders approved increase in 2018 Equity Plan from 14M to 20.7M shares (6.7M new shares).","Other proposals: executive compensation (advisory) and auditor ratification passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-070604","json":"https://secwatch.observer/filing/0001104659-22-070604.json","markdown":"https://secwatch.observer/filing/0001104659-22-070604.md","text":"https://secwatch.observer/filing/0001104659-22-070604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/0001104659-22-070604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/tm2218321d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:17:58.261510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"924f9c660f","claim":"Wendy Dixon was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..","evidence_excerpt":"appointed Wendy Dixon, Ph.D., as a director and new member of the Board, effective June 10, 2022, to fill such newly created vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/0001104659-22-070604-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}